News

Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields
Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn ...
Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...
Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)
Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after ...
Why Bristol-Myers Squibb (BMY) Stock Is Trading Lower Today
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company ...
Bristol Myers posts better-than-expected second quarter results on strength of top sellers
By Michael Erman (Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on ...
BioPharma Dive3d
Bain leads $300M investment in startup built on Bristol Myers immune drugs
Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...
Bristol-Myers Squibb shares snap six-session losing streak
Bristol-Myers Squibb (BMY) shares rebound after recent losses. Analysts weigh in on its value, growth potential, and updated ...
Bristol Myers, Bain Capital form new company to develop immunology drugs
Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...